Jazz Pharmaceuticals PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Renee D Gala, President & CEO and a Director of Jazz Pharmaceuticals plc, sold 2,000 shares of common stock on October 6, 2026 for $236.40 per share.
NASDAQ
Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, sold 6,000 shares of common stock on October 1, 2026 for $230.33 per share.
NASDAQ
Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals plc, sold 1,200 shares of common stock on September 10, 2026 for $240.94 per share.
NASDAQ
Renee D Gala, President & CEO of Jazz Pharmaceuticals plc, sold 2,000 shares of common stock on September 8, 2026 for $243.03 per share.
NASDAQ
Mary Elizabeth Henderson, SVP, Technical Operations of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on September 8, 2026.
NASDAQ
Mary Elizabeth Henderson, SVP, Technical Operations of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Mark Douglas Smith, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Norbert G Riedel, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Ted W Love, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Laura Hamill, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Jennifer E. Cook, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Patrick G Enright, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Heather Ann Mcsharry, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Patrick Kennedy, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Rick E Winningham, a Director of Jazz Pharmaceuticals plc, reported multiple transactions in common stock on August 31, 2026.
NASDAQ
Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, sold 6,000 shares of common stock on August 31, 2026 for $250.13 per share.
NASDAQ
Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc, sold 76,921 shares of common stock on August 27, 2026.
NASDAQ
Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals plc, reported a transaction in 780 shares of common stock on August 5, 2026.
NASDAQ
Rick E Winningham, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Ted W Love, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Laura Hamill, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Patrick Kennedy, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Mark Douglas Smith, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Jennifer E. Cook, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Seamus Mulligan, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Heather Ann Mcsharry, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Patrick G Enright, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Norbert G Riedel, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.
NASDAQ
Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, sold 6,000 shares of common stock on August 3, 2026 for $252.98 per share.